Horizon Therapeutics Public (NASDAQ:HZNP) Stock Rating Lowered by UBS Group

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a report released on Thursday, The Fly reports. They presently have a $71.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $137.00. UBS Group’s price target indicates a potential upside of 2.01% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. SVB Leerink started coverage on shares of Horizon Therapeutics Public in a research report on Monday, May 23rd. They issued a “market perform” rating and a $95.00 target price for the company. Oppenheimer reaffirmed a “buy” rating and set a $140.00 price target on shares of Horizon Therapeutics Public in a report on Friday, July 8th. Finally, Wells Fargo & Company reaffirmed a “buy” rating and set a $133.00 price target on shares of Horizon Therapeutics Public in a report on Friday, April 8th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Horizon Therapeutics Public presently has a consensus rating of “Moderate Buy” and an average target price of $117.22.

Horizon Therapeutics Public Price Performance

Shares of NASDAQ:HZNP opened at $69.60 on Thursday. The firm has a 50 day moving average of $83.03 and a 200-day moving average of $93.34. The stock has a market capitalization of $16.03 billion, a PE ratio of 21.48, a PEG ratio of 1.13 and a beta of 1.12. The company has a current ratio of 4.05, a quick ratio of 3.30 and a debt-to-equity ratio of 0.52. Horizon Therapeutics Public has a 12 month low of $60.76 and a 12 month high of $120.54.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.36 by ($0.29). The firm had revenue of $876.40 million during the quarter, compared to analyst estimates of $938.82 million. Horizon Therapeutics Public had a net margin of 20.06% and a return on equity of 27.90%. Horizon Therapeutics Public’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.62 earnings per share. On average, equities research analysts predict that Horizon Therapeutics Public will post 5.68 EPS for the current fiscal year.

Insider Activity at Horizon Therapeutics Public

In related news, CEO Timothy P. Walbert sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $92.48, for a total transaction of $2,312,000.00. Following the transaction, the chief executive officer now owns 435,549 shares in the company, valued at approximately $40,279,571.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Horizon Therapeutics Public news, CEO Timothy P. Walbert sold 17,600 shares of the company’s stock in a transaction on Wednesday, May 11th. The shares were sold at an average price of $90.00, for a total transaction of $1,584,000.00. Following the transaction, the chief executive officer now owns 460,549 shares in the company, valued at $41,449,410. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Timothy P. Walbert sold 25,000 shares of the stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $92.48, for a total transaction of $2,312,000.00. Following the completion of the sale, the chief executive officer now owns 435,549 shares of the company’s stock, valued at approximately $40,279,571.52. The disclosure for this sale can be found here. Insiders have sold 98,384 shares of company stock worth $8,934,633 in the last quarter. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Horizon Therapeutics Public

A number of large investors have recently modified their holdings of HZNP. State Board of Administration of Florida Retirement System raised its stake in Horizon Therapeutics Public by 2.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 268,141 shares of the biopharmaceutical company’s stock valued at $21,387,000 after purchasing an additional 5,683 shares in the last quarter. M&T Bank Corp boosted its holdings in Horizon Therapeutics Public by 41.9% in the second quarter. M&T Bank Corp now owns 44,313 shares of the biopharmaceutical company’s stock valued at $2,350,000 after acquiring an additional 13,092 shares in the last quarter. Lebenthal Global Advisors LLC boosted its holdings in Horizon Therapeutics Public by 5.8% in the second quarter. Lebenthal Global Advisors LLC now owns 2,669 shares of the biopharmaceutical company’s stock valued at $212,000 after acquiring an additional 147 shares in the last quarter. Oakworth Capital Inc. boosted its holdings in Horizon Therapeutics Public by 554.4% in the second quarter. Oakworth Capital Inc. now owns 2,081 shares of the biopharmaceutical company’s stock valued at $166,000 after acquiring an additional 1,763 shares in the last quarter. Finally, Riverwater Partners LLC bought a new stake in shares of Horizon Therapeutics Public during the 2nd quarter valued at $211,000. 88.39% of the stock is currently owned by institutional investors.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Read More

The Fly logo

Analyst Recommendations for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.